HANSA MEDICAL AB ORD news, videos and press releases - Page 3
For more news please use our advanced search feature.
HANSA MEDICAL AB ORD - More news...
HANSA MEDICAL AB ORD - More news...
- Hansa Biopharma: Increase of the number of shares and votes
- Hansa Biopharma Nomination Committee formed
- Hansa Biopharma announces positive reimbursement decision in Italy for Idefirix® (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation
- Hansa Biopharma announces positive topline data from the imlifidase phase 2 study in antibody mediated rejection (AMR) episodes post kidney transplantation
- Hansa Biopharma and partner Sarepta Therapeutics plan to initiate a clinical study with imlifidase as a pre-treatment to Sarepta's SRP-9001 gene therapy in DMD in 2023
- Hansa Biopharma Interim report January-September 2022
- Hansa Biopharma: Increase of the number of shares and votes
- Hansa Biopharma to host conference call to provide interim results for January-September 2022 and Business Update
- Hansa Biopharma achieves Great Place to Work® certification for the third consecutive year
- The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma's Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
- Hansa Biopharma: Issue and repurchase of class C shares for incentive programs
- Hansa Biopharma and Medison Pharma announce positive reimbursement decision in Poland for Idefirix® in highly sensitized kidney transplant patients
- European Society for Organ Transplantation's (ESOT) guidelines for desensitization treatment of highly sensitized kidney transplant patients published in Transplant International
- Hansa Biopharma half year report 2022
- Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company's antibody-cleaving enzyme technology platform
- Hansa Biopharma announces first patient treated in the post-authorization efficacy study (PAES) of Idefirix® (imlifidase) in highly sensitized kidney transplant patients
- Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)
- NICE recommends use of Hansa Biopharma's Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
- Hansa Biopharma: Notice to Annual General Meeting
- The Nomination Committee in Hansa Biopharma proposes Peter Nicklin as new chair of the Board of Directors at the Annual General Meeting 2022
- Hansa Biopharma completes enrollment in imlifidase phase 2 study in antibody mediated rejection (AMR) episodes post kidney transplantation
- Hansa Biopharma interim report January - March 2022
- Hansa Biopharma publishes Annual Report 2021
- Hansa Biopharma and German payer head association agree on reimbursement price for Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
- Hansa Biopharma year-end report 2021
- Hansa Biopharma provides business update including certain key financials
- Hansa Biopharma enters into agreement with AskBio to evaluate feasibility of imlifidase as pre-treatment ahead of gene therapy in Pompe disease
- Hansa Biopharma enrolls first patient in U.S. randomized, controlled pivotal trial of imlifidase in highly sensitized kidney transplant patients
- Hansa Biopharma and Medison Pharma announce multiregional commercialization partnership for Hansa's desensitization treatment for kidney transplant in Central Eastern Europe and Israel
- Hansa Biopharma to initiate Phase 3 study of imlifidase to treat anti-Glomerular Basement Membrane (anti-GBM) disease after successful pre-IND meeting with U.S. FDA
